TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05938127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle strength training
Description: High-resistance inspiratory muscle strength training (IMST) is a time-efficient (\~5 minutes/day) form of exercise that employs an affordable, handheld device which impedes inspiratory breathing to train the diaphragm and accessory respiratory muscles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Inspiratory muscle strength training
Description: Low-resistance inspiratory muscle strength training
Study: NCT05096949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visit delivery strategy
Description: A nurse will deliver and administer Cabenuva injection at patient's home
Study: NCT05278429

Intervention type: DEVICE
Group type: OTHER
Intervention: Myosuit robotic device
Description: The Myosuit is a partially soft, exoskeleton-type, wearable robot that supports the synergistic extension of the hip and knee joints.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myosuit robotic device
Description: The Myosuit is a partially soft, exoskeleton-type, wearable robot that supports the synergistic extension of the hip and knee joints.
Study: NCT04856904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifarotene Cream
Description: Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream to the face once daily, in the evening for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trifarotene Vehicle Cream
Description: Participants will apply a thin a layer of trifarotene vehicle cream to the face once daily, in the evening for 24 weeks
Study: NCT03597594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-thymocyte globulin (rabbit)
Description: given intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: given intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: given intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa
Description: given intravenous infusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion
Description: given intravenous infusion
Study: NCT04896593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone App
Description: Smartphone app teaching suicide prevention skills.
Study: NCT06045091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human BCMA targeted CAR-NK cells injection
Description: Allogenic genetically modified anti-BCMA CAR transduced NK cells
Study: NCT05788913

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: subcutaneous Heparin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heparin
Description: subcutaneous Heparin
Study: NCT05944146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: passive leg raising
Description: transfer a patient from semi-recumbent position to supine position with a 45° leg lifting
Study: NCT05742451

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kids yoga
Description: The kids yoga was applied to the intervention group for 8 weeks, once a week (8 sessions), 40 minutes per session, by a yoga instructor occupational therapist.~Kids yoga training included: 5-minute warm-up consisting of jogging, jumping, stretching, relaxation exercises; 20 minutes of asanas (positions) consisting of standing, sitting, prone, supine postures and pranayamas (breathing exercises) consisting of vigorous inspiration and expiration, slow and rhythmic alternating nostril breathing; 10-minute yogic games about balance, reaction time and agility; meditation with focus for 5 minutes with resuscitation techniques.
Study: NCT04338295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tattoo machine (SOL Nova Device)
Description: A SOL Nova Device (brand) tattoo machine will be used to stimulate hair regrowth.
Study: NCT05305872

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gandouling
Description: The experimental group was given gandouling tablet + zinc gluconate simulant; The course of treatment was 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gandouling
Description: The experimental group was given gandouling tablet + zinc gluconate simulant; The course of treatment was 24 weeks.
Study: NCT04821206

Intervention type: DRUG
Intervention: DMARDs
Description: New Initiation of a DMARDs

Intervention type: DRUG
Intervention: biologic DMARDs
Description: New Initiation of a biologic DMARDs

Intervention type: DRUG
Intervention: JAK Inhibitor
Description: New Initiation of a JAK Inhibitor
Study: NCT06061393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venofer 200 MG Per 10 ML Injection
Description: treat anemia with venofer up to 5 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject
Description: ferinject 500 mg, once a week for 2 weeks
Study: NCT05817136

Intervention type: DIAGNOSTIC_TEST
Intervention: Eko DUO
Description: Acquisition of a single-lead ECG via patients self-examine themselves twice a week for 12 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: Eko DUO
Description: Acquisition of a single-lead ECG via patients self-examine themselves twice a week for 12 months.
Study: NCT05140031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNE4Adults
Description: It is a clear and concise program, that consists of a manual for the physiotherapist delivering the education and a board game to enhance engagement and participant involvement. It not only provides the physiotherapist with a clear how-to manual but also provides an easy and accessible way for the patient to grasp the difficult and complex concept of pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PNE4Adults
Description: It is a clear and concise program, that consists of a manual for the physiotherapist delivering the education and a board game to enhance engagement and participant involvement. It not only provides the physiotherapist with a clear how-to manual but also provides an easy and accessible way for the patient to grasp the difficult and complex concept of pain.
Study: NCT06537349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Diquafosol tetrasodium
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in OK lens related dry eye
Study: NCT05316012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart diapers
Description: Residents receive standard continence care while using the smart diaper (without the alerting system) - fase 1~Diapers are changed as usual, e.g., after morning care, visual soiling, unpleasant odor, saturation, leakage.~Residents receive continence care while using the smart diaper with the alerting system - fase 2
Study: NCT05944146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: infusion dobutamine
Study: NCT04695860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Burosumab
Description: Q4w, 1mg/kg Body weight, s.c.
Study: NCT04762472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast Oral Tablet
Description: i) Montelukast 10mg daily (tablet) orally x 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast Placebo Oral Tablet
Description: i) Placebo (Montelukast identical) tablet 1 daily orally x 26weeks
Study: NCT05444894

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EDIT-301
Description: Administered by intravenous infusion after myeloablative conditioning with busulfan.
Study: NCT05131191

Intervention type: DIAGNOSTIC_TEST
Intervention: CT-FFR measurement
Description: Patients were scanned with ≥ 64 row CT according to standard operating specifications. The software obtains the coronary CT angiography image file through the data communication interface. Based on the image processing algorithm, the centerline and contour of the target vessel can be extracted, and then the target vessel can be reconstructed to obtain the three-dimensional size information of the vessel; Based on hydrodynamics calculation and analysis, the fractional flow reserve (FFR) of each position of the target vessel is measured.

Intervention type: PROCEDURE
Intervention: invasive FFR
Description: Insert the pressure guide wire into the finger guide tube and push the pressure guide wire until the pressure sensor just comes out of the orifice of guiding catheter; Equalize PD and PA values;Push the pressure guide wire to the distal end of the lesion, and record the measured blood vessel and position;Record the resting Pd / PA of the pressure guide wire;Nitroglycerin and adenosine triphosphate were administered intravenously according to standard catheter laboratory specifications to achieve maximum hyperemia;Record the FFR value of the in-stent lesions.
Study: NCT05047081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scoring Your College Goals Workshop
Description: A two-hour virtual college readiness workshop.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Treatment-As-Usual Group which does not receive the workshop intervention
Study: NCT05627882

Intervention type: DIAGNOSTIC_TEST
Intervention: Forward viewing endoscope
Description: Additional examination with standard forward viewing endoscope
Study: NCT05767632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose)
Description: 1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirfenacin MR (Solifenacin Succinate 5 mg & Mirabegron 50 mg) (Test)
Description: 1 tablet Mirfenacin MR contains Solifenacine succinate 5 mg \& Mirabegron 50 mg orally administrated followed by 240 ml of water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose)
Description: 1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
Study: NCT05543512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algorithm to diagnose food allergens
Description: An algorithm to diagnose food allergens that will drive diet intervention assignment for those in the active arm. Subjects randomized to this group will receive a diet assignment based on results of the algorithm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham diet
Description: Sham diet developed via selecting a random number of foods from a random list of the potential eliminated foods.
Study: NCT03877627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic and Peritoneal Lymphadenectomy
Description: Patients in arm 2 will be randomized to undergo pelvic and peritoneal lymphadenectomy to treat their endometrial carcinoma.
Study: NCT05768984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Empowerment program
Description: It is planned to conduct the empowerment program online (zoom session). For this, to protect each individual's privacy, a quiet, bright and ventilated, spacious physical environment and technological elements such as computers, headphones, microphones and internet connection are needed. The empowerment program was planned as a total of 10 sessions, one session per week. In the program, goals and objectives have been established for each session. These aims and objectives will be shared with the participants before each session. The application time of each session is planned as an average of 90 minutes.
Study: NCT05067738

Intervention type: OTHER
Group type: OTHER
Intervention: same day discharge
Description: same day discharge
Study: NCT06224842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone liposome 16 and azacitidine
Description: The mitoxantrone liposome will be intravenous infused at a dose of 16mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone liposome 18 and azacitidine
Description: The mitoxantrone liposome will be intravenous infused at a dose of 18mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone liposome 20 and azacitidine
Description: The mitoxantrone liposome will be intravenous infused at a dose of 20mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
Study: NCT05511142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic Peyton's Four-Step Approach
Description: Instructor demonstrated endotracheal intubation and mask ventilation procedural skills directly to the preclinical students, followed by direct hands-on practice using manequin, ended with giving feedback to the students

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Peyton's Four-Step Approach
Description: Video tutorial of endotracheal intubation and mask ventilation were given to the students without explanation, followed by video tutorial making using manequin (without instructor) by the students which will be uploaded to Youtube
Study: NCT06551480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biometry
Description: Only one eye from each patient will be included in the study. All subjects and patients included in the study will undergo biometric measurements with both devices (IOL master 500 and VCSEL based swept source optical biometry).
Study: NCT05159895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-DZD9008
Description: Each subject will receive a total of 100 mg DZD9008 oral suspension containing approximately 1 μCi of \[14C\] as a single administration
Study: NCT05673642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Techniques
Description: Myofascial Release Technique (MFR), which we will apply to the muscles we choose related to the facial system connection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Techniques
Description: Myofascial Release Technique (MFR), which we will apply to the muscles we choose related to the facial system connection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Techniques
Description: Myofascial Release Technique (MFR), which we will apply to the muscles we choose related to the facial system connection
Study: NCT06377397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: In experimental arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered selectively to those newborn infants who later develop clinical signs of sepsis according to a predefined repertory of clinical signs.~In active comparator arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered pre-emptively to all newborn infants from enrollment even if they do not have any clinical signs of sepsis at enrollment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: In experimental arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered selectively to those newborn infants who later develop clinical signs of sepsis according to a predefined repertory of clinical signs.~In active comparator arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered pre-emptively to all newborn infants from enrollment even if they do not have any clinical signs of sepsis at enrollment
Study: NCT05422781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-3000
Description: ITI-3000 is a DNA vaccine (L-H LT S220A) which contains sequences for both LAMP1 and LTS220A, the truncated form of the LT antigen of MCPyV with a detoxifying serine to alanine mutation at position 220
Study: NCT04931056

Intervention type: DEVICE
Intervention: Titanium Facial Plates
Description: The Facial Plating System provides a comprehensive titanium fixation solution for maxillofacial surgery procedures. More than twenty-five different plating options in two systems, the 1.5 mm and 2.0 mm with a variety of instruments, and high torque screws, including meshes, are part of this system. Plates and screws are made of commercially pure titanium per ASTM F-67, Titanium 6Al 4V Alloy per ASTM F-136.

Intervention type: DEVICE
Intervention: Titanium Mandibular Plates
Description: The Mandibular Plating System provides a comprehensive titanium fixation solution for mandibular surgical procedures. Several plating options, a variety of instruments, and high torque screws with various plate shapes are part of this system.~Plates in the Mandibular Plating System have profiles of various thicknesses. Screws are available in self-tapping, locking and non-locking varieties, and in various sizes between 2.0 mm and 2.3 mm in diameter, and 5 mm to 18 mm in length.

Intervention type: DEVICE
Intervention: Add-on Condyle
Description: The Add-On Condyle is intended to be implanted in the human jaw to replace the mandibular condyle to functionally reconstruct the temporomandibular joint on a temporary basis for patients undergoing ablative tumor surgery requiring the removal of the native mandibular condyle. This device is not for permanent implantation, traumatic injuries, or for treatment of temporomandibular joint disease.

Intervention type: DEVICE
Intervention: HTR-PEKK
Description: The HTR-PEKK implants are fabricated from polyether-ketone-ketone (PEKK) via selective laser sintering (SLS), a 3D manufacturing technique. The laser sintering machine builds the implant in layers as dictated from a stereolithographic (STL) file of the approved implant. The HTR-PEKK implants are designed individually for each patient to replace bony voids in the facial anatomy using a patient's own CT imaging data. The implant is made to fill an existing or planned void (where appropriate) using computer-aided design technology for anatomy enhancement, correction of trauma injuries, and/or to correct congenital defects in the craniofacial bone.
Study: NCT04667039

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GNR-067
Description: GNR-067 will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lucentis®
Description: Lucentis® will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
Study: NCT05506202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual basic body awareness therapy
Description: Basic Body Awareness Therapy (BBAT) is a physiotherapeutic intervention directed toward patients' functional movement quality. The development of BBAT was based on the hypothesis of persons' lacking contact with and lacking awareness on their own body, with their inner life, external environment and in the relation to other persons. Thus, it leads to dysfunctional movement, pain and other body functions. BBAT focus on multi-perspective within a person including physical, physiological, psycho-social-cultural and existential perspectives. It directs patients to be aware, guides patients to have mental contact with their body, monitors internal sensations and external environment, and thus, to enhance the self-regulated behavior and positive emotional state.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory physiotherapy interventions
Description: Comprehensive physical and psycho-social assessment and treatments are included. Both basic and advanced respiratory physiotherapy interventions, including respiratory muscles training, breathing techniques, bronchial hygiene maintenance, assisting in non-invasive ventilation therapy and oxygen therapy titration, are provided according to assessment findings.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy interventions
Description: Comprehensive physical and psycho-social assessment and treatments are included. Both basic and advanced respiratory physiotherapy interventions, including respiratory muscles training, breathing techniques, bronchial hygiene maintenance, assisting in non-invasive ventilation therapy and oxygen therapy titration, are provided according to assessment findings.
Study: NCT05620576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3857210
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT06438042

Intervention type: DEVICE
Intervention: Use of a powered low air pressure motorised therapeutic mattress that combines the motorised and static technologies
Description: Patients with a high risk of pressure injury, without pressure injury, lying more than 20 hours a day, will ly a on a XTECH®25 mattress
Study: NCT05250024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UHMWP Cranioplasty
Description: patient specific cranial implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEEK Cranioplasty
Description: patient specific cranial implant
Study: NCT03462212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: chemotherapy medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: chemotherapy medication

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: chemotherapy medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: chemotherapy medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: chemotherapy medication

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: chemotherapy medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Angiogenesis inhibitor

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Angiogenesis inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: PARP inhibitor